Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_assertion type Assertion NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_head.
- NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_assertion description "[The predicted mean percentages of the subjects with ?-GT elevation were about 2- to 3-fold, 3- to 4-fold and 4- to 8-fold greater in patients with the SOD2 Val/Val genotype but without any intellectual disability, those with the SOD2 Val/Ala or Ala/Ala genotype and intellectual disability and those with the SOD2 Val/Val genotype and intellectual disability, respectively, compared to those with the SOD2 Val/Ala or Ala/Ala genotype without intellectual disability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_provenance.
- NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_assertion evidence source_evidence_literature NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_provenance.
- NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_assertion SIO_000772 25372290 NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_provenance.
- NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_assertion wasDerivedFrom befree-2016 NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_provenance.
- NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_assertion wasGeneratedBy ECO_0000203 NP1235223.RAoiYn3FGS73ZbwLLqd1R2ySq7JsvQLWrVyzPbcoRmgG4130_provenance.